Syndax Pharmaceuticals Stock Today
| SNDX Stock | USD 20.06 0.16 0.79% |
PerformanceFair
| Odds Of DistressSmall
|
Syndax Pharmaceuticals is trading at 20.06 as of the 6th of January 2026; that is 0.79 percent decrease since the beginning of the trading day. The stock's open price was 20.22. Syndax Pharmaceuticals has about a 40 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 8th of October 2025 and ending today, the 6th of January 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 3rd of March 2016 | Category Healthcare | Classification Health Care |
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts. Syndax Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 86.91 M outstanding shares of which 22.83 M shares are at this time shorted by private and institutional investors with about 10.84 trading days to cover. More on Syndax Pharmaceuticals
Moving together with Syndax Stock
Moving against Syndax Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Syndax Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President Development | Neil MD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSyndax Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Syndax Pharmaceuticals' financial leverage. It provides some insight into what part of Syndax Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Syndax Pharmaceuticals (SNDX) is traded on NASDAQ Exchange in USA and employs 270 people. Syndax Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.85 B. Syndax Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 86.91 M outstanding shares of which 22.83 M shares are at this time shorted by private and institutional investors with about 10.84 trading days to cover.
Syndax Pharmaceuticals currently holds about 350.71 M in cash with (274.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.82.
Check Syndax Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe majority of Syndax Pharmaceuticals outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Syndax Pharmaceuticals to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Syndax Pharmaceuticals. Please pay attention to any change in the institutional holdings of Syndax Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.
Check Syndax Ownership Details
Syndax Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Kingdon Capital Management Llc | 2025-06-30 | 2.1 M | |
| Geode Capital Management, Llc | 2025-06-30 | 2 M | |
| Assenagon Asset Management Sa | 2025-06-30 | 2 M | |
| Woodline Partners Lp | 2025-06-30 | 1.9 M | |
| Qube Research & Technologies | 2025-06-30 | 1.7 M | |
| Millennium Management Llc | 2025-06-30 | 1.6 M | |
| Sphera Funds Management Ltd. | 2025-06-30 | 1.6 M | |
| Sofinnova Ventures | 2025-06-30 | 1.5 M | |
| Bnp Paribas Investment Partners Sa | 2025-06-30 | 1.4 M | |
| Blackrock Inc | 2025-06-30 | 10.5 M | |
| Kynam Capital Management, Lp | 2025-06-30 | 8.5 M |
Syndax Pharmaceuticals Historical Income Statement
Syndax Stock Against Markets
Syndax Pharmaceuticals Corporate Management
| Briggs MD | Head Pres | Profile | |
| Steven Closter | Chief Officer | Profile | |
| Michael MBA | CEO Director | Profile | |
| Steve Sabus | Chief Officer | Profile | |
| Joseph MD | Member Officer | Profile | |
| Ronald Evans | Advisor CoFounder | Profile | |
| Sharon Klahre | Vice Communications | Profile |
Additional Tools for Syndax Stock Analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.